Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4458 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26 |
filingDate |
2017-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2020-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020502091-A |
titleOfInvention |
Compositions comprising methylphenidate-prodrugs, methods of making and using the same |
abstract |
The present technology relates to compositions comprising a d-threomethylphenidate conjugate and unbound methylphenidate. The technology also includes d-threomethylphenidate conjugated to nicotinoyl-L-serine and / or a pharmaceutically acceptable salt thereof, and unbound methylphenidate and / or a pharmaceutically acceptable salt thereof. Compositions and oral formulations. The technology also includes d-threomethylphenidate conjugated to nicotinoyl-L-serine and / or a pharmaceutically acceptable salt thereof, and unbound methylphenidate and / or a pharmaceutically acceptable salt thereof. It relates to a pharmaceutical kit containing the composition. |
priorityDate |
2016-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |